JP2018512406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018512406A5 JP2018512406A5 JP2017548980A JP2017548980A JP2018512406A5 JP 2018512406 A5 JP2018512406 A5 JP 2018512406A5 JP 2017548980 A JP2017548980 A JP 2017548980A JP 2017548980 A JP2017548980 A JP 2017548980A JP 2018512406 A5 JP2018512406 A5 JP 2018512406A5
- Authority
- JP
- Japan
- Prior art keywords
- acceptable salt
- stereoisomer
- pharmaceutically acceptable
- diastereomer
- enantiomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 20
- 239000012453 solvate Substances 0.000 claims 19
- -1 alkyl carboxylic acids Chemical class 0.000 claims 13
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 229920006395 saturated elastomer Polymers 0.000 claims 9
- 206010016654 Fibrosis Diseases 0.000 claims 8
- 230000004761 fibrosis Effects 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 5
- 150000004677 hydrates Chemical class 0.000 claims 5
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 claims 2
- 206010028594 Myocardial fibrosis Diseases 0.000 claims 2
- 238000009825 accumulation Methods 0.000 claims 2
- 150000003973 alkyl amines Chemical class 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 208000019425 cirrhosis of liver Diseases 0.000 claims 2
- 230000001934 delay Effects 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 claims 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 201000002793 renal fibrosis Diseases 0.000 claims 2
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001188 haloalkyl group Chemical class 0.000 claims 1
- 125000001475 halogen functional group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 239000002904 solvent Substances 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 125000001425 triazolyl group Chemical group 0.000 claims 1
- 0 C*C(C(N1)=O)NC1=O Chemical compound C*C(C(N1)=O)NC1=O 0.000 description 2
- LMRLPPWNVOYTCQ-UHFFFAOYSA-N CC(C)C(C(C)(N1)O)OC1=O Chemical compound CC(C)C(C(C)(N1)O)OC1=O LMRLPPWNVOYTCQ-UHFFFAOYSA-N 0.000 description 1
- SSMDYRHBKZVGNR-UHFFFAOYSA-N CC(C)C(C(N1)=O)=CC1=O Chemical compound CC(C)C(C(N1)=O)=CC1=O SSMDYRHBKZVGNR-UHFFFAOYSA-N 0.000 description 1
- GGMXVSSJODBBQA-UHFFFAOYSA-N CC(C)C(O1)=CNC1=O Chemical compound CC(C)C(O1)=CNC1=O GGMXVSSJODBBQA-UHFFFAOYSA-N 0.000 description 1
- GAIOQBNXIHMNHE-UHFFFAOYSA-N CC(C)CC(C(F)(F)F)N Chemical compound CC(C)CC(C(F)(F)F)N GAIOQBNXIHMNHE-UHFFFAOYSA-N 0.000 description 1
- KAJJUFUPJGVIFJ-UHFFFAOYSA-N CC(CC(N1)=O)C1=O Chemical compound CC(CC(N1)=O)C1=O KAJJUFUPJGVIFJ-UHFFFAOYSA-N 0.000 description 1
- GOZPJNMFUQYVMU-UHFFFAOYSA-N COCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 Chemical compound COCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 GOZPJNMFUQYVMU-UHFFFAOYSA-N 0.000 description 1
- QRXBBEOQXMPBDN-BPNWFJGMSA-N C[C@H](CC(OC1Cc(cc(cc2)-c3ccccc3)c2-c2cccc([O]=C)c2)=O)C1=O Chemical compound C[C@H](CC(OC1Cc(cc(cc2)-c3ccccc3)c2-c2cccc([O]=C)c2)=O)C1=O QRXBBEOQXMPBDN-BPNWFJGMSA-N 0.000 description 1
- UWNJCWROXGRALG-UHFFFAOYSA-N OCCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 Chemical compound OCCc(cc(cc1)-c2ccccc2)c1-c1cccc(O)c1 UWNJCWROXGRALG-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2015900979 | 2015-03-18 | ||
| AU2015900979A AU2015900979A0 (en) | 2015-03-18 | Compositions for the treatment of fibrosis | |
| PCT/AU2016/000095 WO2016145479A1 (en) | 2015-03-18 | 2016-03-18 | Compositions for the treatment of fibrosis and fibrosis-related conditions |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018512406A JP2018512406A (ja) | 2018-05-17 |
| JP2018512406A5 true JP2018512406A5 (https=) | 2019-04-11 |
| JP6734294B2 JP6734294B2 (ja) | 2020-08-05 |
Family
ID=56918156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017548980A Active JP6734294B2 (ja) | 2015-03-18 | 2016-03-18 | 線維症及び線維症に関連する状態の処置のための組成物 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US10035775B2 (https=) |
| EP (1) | EP3271320B1 (https=) |
| JP (1) | JP6734294B2 (https=) |
| KR (1) | KR102591689B1 (https=) |
| CN (1) | CN107531598B (https=) |
| AU (1) | AU2016232978B2 (https=) |
| BR (1) | BR112017019824B1 (https=) |
| CA (1) | CA2979413C (https=) |
| DK (1) | DK3271320T3 (https=) |
| ES (1) | ES2766769T3 (https=) |
| IL (1) | IL254505A0 (https=) |
| MX (1) | MX375918B (https=) |
| MY (1) | MY182818A (https=) |
| NZ (1) | NZ736164A (https=) |
| PH (1) | PH12017501694B1 (https=) |
| RU (1) | RU2712140C2 (https=) |
| SG (1) | SG11201707561RA (https=) |
| WO (1) | WO2016145479A1 (https=) |
| ZA (1) | ZA201706985B (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108349872B (zh) * | 2015-09-22 | 2020-12-18 | 维克图斯生物系统有限公司 | 三联苯化合物的合成 |
| MY192402A (en) | 2016-07-28 | 2022-08-19 | Vectus Biosystems Ltd | Compositions for the treatment of pulmonary fibrosis |
| CN118994235A (zh) * | 2023-05-19 | 2024-11-22 | 南京工业大学 | 一种β-三氟甲基取代α，β-不饱和磷酸酯及膦氧化合物的制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2006322656B2 (en) * | 2005-12-09 | 2012-03-08 | Vectus Biosystems Limited | VIP fragments and methods of use |
| FR2904827B1 (fr) * | 2006-08-11 | 2008-09-19 | Sanofi Aventis Sa | Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii |
| US20120088737A2 (en) | 2009-10-02 | 2012-04-12 | Ajinomoto Co., Inc | Novel acyl guanidine derivatives |
| NZ717930A (en) * | 2013-09-17 | 2018-12-21 | Vectus Biosystems Ltd | Compositions for the treatment of hypertension and/or fibrosis |
| MY172557A (en) * | 2013-09-17 | 2019-12-02 | Vectus Biosystems Ltd | Compositions for the treatment of hypertension and/or fibrosis |
-
2016
- 2016-03-18 JP JP2017548980A patent/JP6734294B2/ja active Active
- 2016-03-18 EP EP16764055.6A patent/EP3271320B1/en active Active
- 2016-03-18 NZ NZ736164A patent/NZ736164A/en unknown
- 2016-03-18 DK DK16764055.6T patent/DK3271320T3/da active
- 2016-03-18 MX MX2017011904A patent/MX375918B/es active IP Right Grant
- 2016-03-18 US US15/557,762 patent/US10035775B2/en active Active
- 2016-03-18 WO PCT/AU2016/000095 patent/WO2016145479A1/en not_active Ceased
- 2016-03-18 CN CN201680028430.1A patent/CN107531598B/zh active Active
- 2016-03-18 PH PH1/2017/501694A patent/PH12017501694B1/en unknown
- 2016-03-18 CA CA2979413A patent/CA2979413C/en active Active
- 2016-03-18 AU AU2016232978A patent/AU2016232978B2/en active Active
- 2016-03-18 SG SG11201707561RA patent/SG11201707561RA/en unknown
- 2016-03-18 MY MYPI2017001348A patent/MY182818A/en unknown
- 2016-03-18 KR KR1020177030092A patent/KR102591689B1/ko active Active
- 2016-03-18 RU RU2017135950A patent/RU2712140C2/ru active
- 2016-03-18 ES ES16764055T patent/ES2766769T3/es active Active
- 2016-03-18 BR BR112017019824-0A patent/BR112017019824B1/pt active IP Right Grant
-
2017
- 2017-09-14 IL IL254505A patent/IL254505A0/en active IP Right Grant
- 2017-10-16 ZA ZA2017/06985A patent/ZA201706985B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014503574A5 (https=) | ||
| PH12022550611A1 (en) | Brd9 bifunctional degraders and their methods of use | |
| PH12023550130A1 (en) | Tetrahydropyrazolo-pyrazinyl-dihydroimidazolone or tetrahydropyrazolo-pyridinyl-dihydroimidazolone compounds and methods of using same | |
| EP4574210A3 (en) | Kappa opioid receptor antagonists and products and methods related thereto | |
| PH12020551616A1 (en) | N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof | |
| JP2015537020A5 (https=) | ||
| WO2006069155A3 (en) | Inhibitors of protein arginine methyl transferases | |
| JP2015500326A5 (https=) | ||
| JP2013542261A5 (https=) | ||
| JP2014507455A5 (https=) | ||
| JP2016516043A5 (https=) | ||
| RU2013140484A (ru) | Фармацевтические композиции, содержащие аминосоединение | |
| JP2014129360A5 (https=) | ||
| JP2015522650A5 (https=) | ||
| JP2011509309A5 (https=) | ||
| MX2020013694A (es) | Compuestos heterocíclicos como inhibidores de trk. | |
| RU2007120454A (ru) | Производные хинуклидина и их применение в качестве антагонистов мускариновых рецепторов м3 | |
| AR107633A1 (es) | Procedimiento para la preparación del ácido 4-fenil-5-alcoxicarbonil-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]-3-oxo-5,6,8,8a-tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxílico | |
| PH12019550226A1 (en) | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof | |
| RU2016104844A (ru) | Производные n-мочевино замещенных аминокислот как модуляторы формил-пептидного рецептора | |
| CA2679198A1 (en) | Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases | |
| MX2021008263A (es) | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. | |
| MX344109B (es) | Formulaciones de sal de meglumina del ácido 1-(5,6-dicloro-1h-benz o[d]imidazol-2-il)-1h-pirazol-4-carboxílico. | |
| JP2018512406A5 (https=) | ||
| JP2015502371A5 (https=) |